A clinical trial led by African researchers concluded a year ahead of schedule after it was determined that new combination vaccines have "little or no chance" of reducing the risk of HIV.
The African-led trial, initiated in December 2020, came to an early halt last month following an interim assessment of progress. The conclusive findings are anticipated to be disclosed in late 2024.
